

# **MDV Japanese Hospital Database**

# *Featuring over 40+ million patient records from 460+ hospitals in Japan, integrated with IQVIA analytic tools*

With an established healthcare system and non-restrictive patient access to medicines, Japan is currently the third largest pharmaceutical market in the world — and the second ranked country by protected pharmaceutical brand spend.

# Rapid data analysis and visualization

The Medical Data Vision (MDV) database includes over 40+ million patient records from 460+ hospitals and is one of four available Japanese datasets integrated with IQVIA's Analytics Research Accelerator data analysis and visualization platform.

#### NUMBER OF PATIENTS **TARGET FACILITIES** One of the largest medical databases in Japan Hospitals (DPC Hospitals) Zmillion Facilities Data Availability: April 2008 - May 2022 \*Approximately 34% of advanced treatment hospitals \*Includes 233 cancer therapeutic facilities \*Onset of data submission will differ by each hospital (National appointment: 144/Prefecture appointment: 89) (As of July 2022) **Age Distribution Summary Target Hospital Summary** 0-14 Number of Number of 14.2% Beds Number of 469 15-64 50.7% Facilities Hospitals 20 - 199 117 65 and above 35.1% 165.415 200 - 499 266 Number of Beds Beds Number of Patients 40.42 million 500 -86 Average Number 352 of Beds per Beds Total 469 Facility

### Overview of MDV database

# Medical market growth trends

Innovative specialty products in Japan are reporting double-digit compound growth, and the availability and use of biologics continues to expand. These trends make Japan an essential market for any healthcare company with global aspirations.

# Selected use cases and therapeutic markets

Rapidly identify emerging healthcare trends, inform drug development decisions, and clearly define the treatment journey to prove the value of your products over competitors, across numerous therapies, use cases, and markets.

#### Three major disease markets for MDV data use

These are just a few of the well-matched therapeutic market areas that are well suited for use of MDV data.



### Broad data and treatment coverage

Featuring broad data coverage and rich in therapeutic detail, the MDV database enables rapid insight into treatment patterns, product efficacy, and patient outcomes.

	DETAILS	ΝΟΤΕ
PANEL HOSPITALS	1. 469 DPC hospitals	• Typically, 70-80% of the panels to be filtered
	2. 40million net patients (as of January 2022)	out due to longitudinal incompleteness or lack of outpatient data
DATA COVERAGE	3. Both in-patients and outpatients	• Lab data available with 10% of the panel
	<ol> <li>DPC E and F file, discharge summary, claim, lab result (not including electronic health record)</li> </ol>	<ul> <li>Lab data is only available for biochemical tests, i.e. blood and urine test (blood pressure is not</li> </ul>
	5. Since April 2008, monthly update	available)
	6. Able to analyze up until two months prior to this month	
DATA ITEMS	7. Patient: Anonymized patient ID, age, gender	
	8. Institution: Specialty, bed counts, cancer therapeutic hospital or not	
	9. Drug: Brand, form and strength based on drug code, daily dosage and duration (only for oral drugs)	
	10. Treatment: Procedure, radiation and test/check based on treatment code	
	11. Diagnosis: ICD-10, first diagnosed date, treatment month	
	12. Hospitalization: Hospitalization date, discharge date, discharge summary	

#### Key attributes of MDV data

### **CONTACT US**



To learn more about IQVIA Health Data Assets & Technologies Please contact: <u>RWDandAIinsidesales@iqvia.com</u> iqvia.com/RWD